Capacity debottlenecking led to growth: Shasun Pharma

Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Masteryourmoney Earnings
moneycontrol.com

Home » News » Business

May 25, 2012, 03.59 PM | Source: CNBC-TV18

Capacity debottlenecking led to growth: Shasun Pharma

Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

Like this story, share it with millions of investors on M3

Capacity debottlenecking led to growth: Shasun Pharma

Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

Post Your Comments

Share Cancel

Abhaya Kumar, MD, Shasun Pharmaceuticals
Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

Below is the edited transcript of his interview. Also watch the accompanying video.

Q: What factors contributed to 40% y-o-y growth for the company?

A: Capacity debottlenecking and higher customer demand which we were able to meet on time led to this growth.

Q: Did the deal from the US to supply API drugs boost your income?

A:  Yes, the US deal boosted our income; in addition to that, there has been a growth in supply of MCE molecule in the UK which resulted in good profits and healthy operations.

Q: What EPS are you looking at in FY13?

A: You can expect at least 25% growth in EPS.

Q: What would lead to 25% growth; there is a buzz in the market that another sole supplier deal for a particular drug in the US has just receive USFDA approval. If you could throw some light on any such opportunities which could rise for Shashun Pharma in near future?

A: Shasun has the highest number of phase III molecules in the pipeline and drugs approval rate in the US is also increasing. So, we have more opportunities of getting into supplier position for MCE molecules.

Q: Your debt equity has improved; can you update us on debt figures?

A: Debt-equity was around 3.78 in the beginning of the year, but at the end of FY12 we are at 1.54.

Q: What is your debt target for FY13?

A: Debt will be 1.4 in FY13 because we are investing Rs 250 crore in various projects, for that we are raising some debt and internal accruals. Going forward debt to equity ratio will be less than 1.

Q: What can we expect from the US in terms of growth in FY13?

A: From the UK operations the growth will be around 10-15%, and we expect the overall growth of 30% in top-line for the company. 

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Capacity debottlenecking led to growth: Shasun Pharma

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login